PCI-32765 (Ibrutinib) is a high potent irreversible BTK inhibitor with an IC50 of 0.46 nM for the purified Btk.PCI-32765 (Ibrutinib) is highly active and well tolerated in CLL/SLL pts irrespective of high risk genomic abnormalities. Although follow-up is short, the high response rate and very low progression rate suggests that PCI-32765 (Ibrutinib) may be an important new targeted treatment approach for CLL pts. In ex vivo assays with whole bold, PCI-32765 (Ibrutinib) prevents the activation of human BCR with an IC50 of about 0.2 μM, while not influencing the activation of T cell. Treatment of CD40 or BCR activated CLL cells with PCI-32765 (Ibrutinib) results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-κB. In addition, PCI-32765 (Ibrutinib) prevents activation-induced proliferation of CLL cells in vitro, and effectively inhibits survival signals provided externally to CLL cells from the microenvironment including soluble factors (CD40L, BAFF, IL-6, IL-4, and TNF-α), fibronectin engagement, and stromal cell contact. PCI-32765 is originally developed by Pharmacyclics. And participants is been invited for the phase I clinical trials.
 Arthritis Res Ther. 2011 Jul 13;13(4):R115.
 Blood. 2011 Jun 9;117(23):6287-96.
|Molecular Weight (WM):||440.5|
A collection of 1159 inhibitors
A collection of 271 kinase inhibitors
A collection of 853 FDA approved drugs
A collection of 144 natural products
A collection of 1650 bioactive compounds
A collection of 118 tyrosine kinase inhibitors
Keywords:buy Ibrutinib | Ibrutinib supplier | purchase Ibrutinib | Ibrutinib cost | Ibrutinib manufacturer | order Ibrutinib | Ibrutinib distributor